Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01426256 · ClinicalTrials.gov registry record · Phase 3
Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC Study)
A Phase 3 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 3
- Development phase
- 91
- Enrollment target
NCT01426256 is a Phase 3 study that has completed, run by Emory University. The registered enrollment target is 91 participants.
The verdict
NCT01426256, a Phase 3 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 91 participants
- Enrollment target
Study Summary
The purpose of this study is determine if high-dose vitamin D supplementation improves clinical outcomes related to lung function and immunity in patients with Cystic Fibrosis who are admitted to the hospital with an acute lung infection.
Interventions
- DIETARY_SUPPLEMENT Cholecalciferol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2011-10 |
| Est. Completion | 2017-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01426256
The ClinicalTrials.gov registry entry for NCT01426256 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cholecalciferol is the first listed.
NCT01426256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01426256 about?
NCT01426256 is a clinical study titled "Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC Study)". The purpose of this study is determine if high-dose vitamin D supplementation improves clinical outcomes related to lung function and immunity in patients with Cystic Fibrosis who are admitted to the hospital with an acute lung infection.
What is the current status of trial NCT01426256?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 91 participants. The study started on 2011-10. Estimated completion is 2017-07.
What interventions are being tested in trial NCT01426256?
The interventions under investigation include: Cholecalciferol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01426256?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.